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Immunogenicity testing of Plasmodium falciparum antigens being considered as malaria vaccine candidates
was undertaken in rabbits. The antigens compared were recombinant baculovirus MSP-119 and five Pichia
pastoris candidates, including two versions of MSP-119, AMA-1 (domains I and II), AMA-1MSP-119, and
fused AMA-1/MSP-119). Animals were immunized with equimolar amounts of each antigen, formulated in
Montanide ISA720. The specificities and titers of antibodies were compared using immunofluorescence assays
and enzyme-linked immunosorbent assay (ELISA). The antiparasite activity of immunoglobulin G (IgG) in in
vitro cultures was determined by growth inhibition assay, flow cytometry, lactate dehydrogenase assay, and
microscopy. Baculovirus MSP-119 immunizations produced the highest parasite-specific antibody titers in
immunofluorescence assays. In ELISAs, baculovirus-produced MSP-119 induced more antibodies than any
other single MSP-119 immunogen and three times more MSP-119 specific antibodies than the AMA-1/MSP-119
fusion. Antibodies induced by baculovirus MSP-119 gave the highest levels of growth inhibition in HB3 and 3D7
parasite cultures, followed by AMA-1MSP-119 and the AMA-1/MSP-119 fusion. With the FCR3 isolate
(homologous to the AMA-1 construct), antibodies to the three AMA-1-containing candidates gave the highest
levels of growth inhibition at high IgG concentrations, but antibodies to baculovirus MSP-119 inhibited as well
or better at lower IgG concentrations. The two P. pastoris-produced MSP-119-induced IgGs conferred the lowest
growth inhibition. Comparative analysis of immunogenicity of vaccine antigens can be used to prioritize
candidates before moving to expensive GMP production and clinical testing. The assays used have given
discriminating readouts but it is not known whether any of them accurately reflect clinical protection.
After infection, humans make an antibody response to a
large number of the 5,400 or so proteins encoded by the ma-
laria parasite, Plasmodium falciparum. Tests of the efficacy of
immunization have only been carried out with a few these
proteins. Measurements of antibody or cellular responses to
particular parasite antigens, following normal infection, have
shown both positive and negative correlations with indirect
measures of immune protection from malaria such as reduc-
tion in parasitemia, fever, or anemia (6, 7, 19). However, al-
though immunoepidemiological data have influenced vaccine
research, particularly in the selection of the variable erythro-
cyte surface adhesion antigens as vaccine targets, they have not
provided sufficiently clear insights to support a scientific con-
sensus on prioritizing antigens for vaccine development (21,
23). Malaria vaccine research has thus probably not yet
achieved what has been termed the crucial “simplification of
the complex” step in vaccine development (10).
Given the lack of evidence for a hierarchy of protective
antigens, selection for vaccine development has frequently
been based on the assumption that good vaccine candidates
are likely to be antigens involved in biologically critical pro-
cesses that may be susceptible to disruption by induced anti-
body binding. Prime targets include blocking invasion of liver
hepatocytes by sporozoites, blocking red blood cell invasion by
merozoites, and blocking infected erythrocyte cytoadhesion to
host receptors on endothelium. Of around a hundred candi-
date malaria vaccines in various stages of development at
present, around one-third contain sporozoite antigen se-
quences (circumsporozoite protein [CSP]), a further third of
these prototypes contain merozoite surface protein 1 (MSP-1),
and ca. 10% contain another merozoite protein, apical mem-
brane antigen 1 (AMA-1) (14). These proteins were identified
around a quarter of a century ago. Despite calls for new ideas
in candidate selection, for blood-stage vaccines aimed at inhi-
bition of replication of parasites in erythrocytes, antibody-me-
diated “invasion blockade” by targeting MSPs remains the
paradigm that dominates the field.
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Selection between competing candidates is a process com-
mon to drug and vaccine development programs. One con-
straint on the prioritization of antigens for blood-stage malaria
vaccine development has been the lack of comparative data on
antigenicity and immunogenicity and also of in vitro assays that
have been proven to correlate with in vivo human immune
responses (13, 20). Here we compare antibody titers and the in
vitro functional immunoglobulin G (IgG) activity induced in
rabbits by equimolar amounts of five merozoite surface vaccine
candidate antigens and one combination of two of these anti-
gens, all formulated in Montanide ISA720. The antigens
included three MSP-119-based antigens, “near-wild-type” and
modified versions produced in Pichia, and a baculovirus ver-
sion with additional MSP-1 residues. Pichia pastoris-produced
AMA-1 antigens containing domains I and II, either simply
combined with, or genetically fused to, the modified Pichia-
produced MSP-119 were also assayed. Standard protocols for
enzyme-linked immunosorbent assays (ELISAs), immunofluo-
rescence assays (IFAs), and parasite growth inhibition assays
(GIAs) were carried out in two different laboratories, one
operating with samples that had been blinded to the research-
ers. The significance of the results obtained and the usefulness
of these assays for malaria vaccine candidate selection are
discussed.
MATERIALS AND METHODS
Antigens. The antigens used in the immunizations were as follows.
First, the P. falciparum MSP-119 baculovirus antigen was produced in insect
cells infected with a recombinant baculovirus containing a synthetic GC-en-
riched (codon-optimized) P. falciparum MSP-1 gene fragment (Palo Alto allele)
coding for the 43 N-terminal MSP-1 residues (the 19 residue MSP-1 signal
sequence, which is removed by processing in baculovirus, plus 24 residues from
the PfMSP-1 N-terminal block 1) and including the adjacent 16 amino acid
residues upstream of the “classical” MSP-119 C-terminal sequence added to that
sequence (3). The antigen was produced as an industrial scale (22L) batch by
Serono SA (Geneva, Switzerland) under World Health Organization sponsor-
ship 6 years previously and had been stored at 4°C in lyophilized form.
The second was a version of the MSP-119 protein fragment that has been
genetically engineered to optimize codon usage from the original P. falciparum
allele (Wellcome clone) to that of the expression host and to remove potential
N-glycosylation sites (by alanine replacement of the serine residue in the N-
glycosylation motif) produced in P. pastoris (MSP-119 WT) (9; W. D. Morgan et
al., unpublished data).
The third was a more structurally modified version of the wild-type MSP-119
recombinant antigen (MSP-119 mut) with Cys-2 and Cys-4 replaced (C12I/
C28W), in the process removing the second disulfide bond in the wild-type
protein (C. Uthaipibull et al., unpublished data). Codon optimization to the
expression host usage was also carried out. Engineered modification of the
structure of the recombinant Pichia expressed material was carried out to im-
prove immunogenicity (9, 24).
For the fourth, domains I and II (residues 97 to 442) of AMA-1 (the allele
present in the FVO clone) were expressed in P. pastoris (AMA-1 Pichia). The
gene was engineered for production at the Biomedical Primate Research Centre
(BPRC) (7) to conservatively replace potentially N-glycosylated sites by replace-
ment of residues in the glycosylation motif, as previously described (13). The
recombinant protein is reactive with the invasion-inhibitory, conformation-de-
pendent monoclonal antibody 4G2 (13).
The fifth was a combined vaccine mixing separate preparations of the P.
falciparum AMA-1 ectodomain construct described above with the P. falciparum
MSP-119 C12I/C28W variant lacking one disulfide bond, both P. pastoris pro-
duced (AMA-1 MSP-119 mix).
Finally, the sixth was a combined vaccine genetically fusing the P. falciparum
AMA-1 ectodomain construct with the P. falciparum MSP-119 C12I/C28W vari-
ant described above, expressed in P. pastoris (AMA-1/MSP-119 fusion) (8).
Immunizations. The purified proteins were used to produce polyclonal anti-
sera in New Zealand White rabbits. Antigen was emulsified in Braun Luer-type
syringes without rubber pistons, through a 22-gauge needle, at a ratio of 3 parts
antigen to 7 parts Montanide ISA720 adjuvant (vol/vol). This adjuvant is a
squalene-based metabolizable oil containing a mannide mono-oleate emulsifier
(Seppic S.A., France). Mixtures were used to immunize rabbits intramuscularly.
Equimolar amounts of each antigen (20 g for MSP-119, 80 g for AMA-1, and
100 g for the AMA-1/MSP-119 fusion) dissolved in 0.5 ml of phosphate-buffered
saline (PBS) were used for each immunization. Doses were given at days 0, 28,
and 56. Final bleeds were taken on day 70. Five rabbits were immunized with
each of the six vaccine candidates. Two rabbits (one in the AMA-1 and one in the
MSP-119 wild-type groups) died for reasons unrelated to the immunizations,
resulting in 28 sets of pre- and postimmunization serum samples. The immuni-
zations and serum collection were carried out by Eurogentec SA (Seraing, Bel-
gium). The IFAs, ELISAs, and initial GIAs were performed “blind” at both
testing centers after coding of the samples at the BPRC.
IFAs. Approximately 500 multispot slides were made from a single parasite
culture batch of each of two different P. falciparum laboratory lines, the Well-
come and 3D7 clones. DNA from parasites used for IFA slides was preanalyzed
by PCR and DNA sequencing to determine sequence, and then their AMA-1 and
MSP-119 sequences were checked against the published sequence derived from
these parasite clones. Both clones had an MSP-119 sequence identical to the
published sequence for that clone (11). The AMA-1 (domain 1) sequence of 3D7
was identical to the published P. falciparum Genome Project-derived sequence. The
Wellcome clone domain 1 AMA-1 sequence was, as expected, identical to the
published FVO clone-derived sequence (13). 28 AMA-1 domain 1 amino acid
residues differ between the proteins encoded by the 3D7 and Wellcome clones (8).
Mixed-stage schizont-rich cultures grown under standard conditions to 4 to 6%
parasitemia were washed in PBS and resuspended to a 2% hematocrit. Then, 25
l of this suspension was placed on each spot of 12-well multispot slides (Hend-
ley-Essex, United Kingdom). The slides were dried overnight at room tempera-
ture and then stored with desiccant at 20°C. Immediately before use, the slides
were thawed and fixed with acetone. Serial dilutions of the postimmunization
sera plus control sera (1:50 to 51:51,200) were made in PBS containing 1%
bovine serum albumin and 0.01% sodium azide. Next, 25-l volumes of each
dilution of antiserum were incubated on the multispots for 30 min at room
temperature in a humidified chamber. The slides were washed three times (1, 5,
and 5 min) in PBS and air dried. Each spot was then incubated as described
above, with 15 l of a 1:80 dilution of fluorescein isothiocyanate-conjugated goat
anti-rabbit IgG (Dako, United Kingdom) for 30 min at room temperature. After
three further washes in PBS, the slides were immersed in a solution of 0.1%
(wt/vol) Evans Blue and 0.001% (wt/vol) DAPI (4,6-diamidino-2-phenylindole;
Sigma) in PBS for 5 min to counterstain erythrocytes and parasite nuclei, re-
spectively. The slides were then washed twice in PBS (1 min each wash) and
mounted under coverslips using the antifading agent Citifluor (City University,
London). Parasites were visualized at 600 magnification by DNA-specific
DAPI fluorescence with incident light at 450 to 495 nm. Antibody-reactive
parasites were viewed by fluorescein isothiocyanate fluorescence with incident
light of 390 to 440 nm. Reading of all slides was carried out “blind” by two
experienced microscopists.
ELISAs. Antisera were tested by ELISA for their ability to recognize the
recombinant antigens used as immunogens. Proteins were either redissolved if
lyophilized in water or used directly if supplied as frozen aliquots. Protein
concentrations were determined by BCA assay using bovine serum albumin
(Pierce) as a standard. Each antigen was coated onto the wells of 96-well plates
(Immulon-4 HBX; Thermo Dynex Inc.) at 0.5 g ml1 in 0.1 ml of coating buffer
(15 mM Na2CO3, 35 mM NaHCO3 [pH 9.3]) overnight at 4°C. This coating
concentration was chosen after initial checkerboard titrations of antigens 1 to 4
with positive control sera. At this antigen concentration, it was possible to
achieve maximum absorbance with positive control sera and minimum back-
ground reactivity with negative control sera, without loss of specificity. For
reasons of sample availability, the antigens, as described above, were absorbed
onto the test wells as follows: 1, MSP-119 baculovirus produced; 2, MSP-119 E.
coli produced; 3, MSP-119 P. pastoris produced; 4, AMA-1 P. pastoris produced;
and 5, AMA-1/MSP-119 P. pastoris produced fusion protein.
ELISA was performed with all rabbit antisera, against the above antigens, in
duplicate on the same day with the same batch of ELISA plates. Each plate
contained a positive control titration. The standard antiserum pool used for the
standard curves on each plate was prepared by combining, in equal amounts, two
other pools of high-titer rabbit antisera specific for AMA-1 and MSP-119, re-
spectively. The standard pool was used at a maximum concentration of 1:8,000,
titrated in doubling dilutions, in duplicate, to a final dilution of 1:512,000. Each
test serum was titrated over eight titration points in duplicate from 1:1,000 to
1:128,000. Each antigen was coated onto separate plates, and the same pooled,
positive standard dilutions were applied to control wells on each plate.
After antigen coating, the wells of each plate were washed three times in
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washing buffer (0.05% Tween 20 in PBS). Unoccupied protein binding sites were
blocked with 0.2 ml of blocking buffer (1% [wt/vol] skimmed milk powder in
washing buffer) per well for 5 h at room temperature and washed again three
times. Doubling dilutions (1:1,000 to 1:128,000) of rabbit sera in blocking buffer
(0.1 ml per well) were added to duplicate antigen-coated wells, followed by
incubation overnight at 4°C. After three washes, the wells were incubated for 3 h
with 0.1 ml per well of horseradish peroxidase-conjugated polyclonal goat anti-
rabbit IgG (at a 1:2,000 dilution) (Dako, Ltd., High Wycombe, United Kingdom)
and then washed three times. Horseradish peroxidase substrate (0.4 mg of
o-phenylenediamine ml1 and 0.012% H2O2) in development buffer (24.5 mM
citric acid monohydrate and 52 mM Na2HPO4 [pH 5.0]) was added to each well
(0.1 ml), followed by incubation for 15 min at room temperature. The reaction
was stopped with 25 l of 2 M H2SO4, and the absorbance was measured at 492
nm in a Multiskan Ascent plate reader (Thermo LabSystems, United Kingdom).
The titer for each rabbit serum was determined by using the curve-fit algorithm
within the Multiskan Ascent (version 2.4.1.) software for the ELISA reader. This
algorithm plots the standard curve for the positive control serum pool for each
plate, using four-parameter logistic regression, and then calculates the antibody
titer as a factor of the positive control. Positive control serum at its lowest
dilution (1:8,000) was given an arbitrary value of 1,000 U, from which titers were
determined.
A slightly different ELISA protocol was used at the BPRC, where ELISA was
performed in duplicate on serum samples in 96-well flat-bottom microtiter plates
(Greiner, Alphen a/d Rijn, The Netherlands). Wells were coated with 500 ng of
purified AMA-1 or MSP-119 antigens ml1 in PBS (pH 7.5) according to pub-
lished methods (13). The sequence of reagents from the solid phase outwards
was protein, antibody, alkaline phosphatase conjugate, and substrate. A stan-
dard curve with known amounts of antigen-specific IgG was used on each
plate, and the concentrations of the unknowns were calculated by using a
four-parameter fit.
IgG purification. IgG purification from all 28 experimental and control rabbit
sera was carried out by affinity chromatography on HiTrap Protein G columns
using an Åktaprime automated chromatography system (Amersham GE Health-
care). Serum samples diluted in PBS were passed through 0.2 m filters (Mini-
sart NML; Sartorius) before application to the column, thoroughly prewashed to
remove unbound proteins before elution of the IgG with 0.1 M glycine-HCl (pH
2.7). Fractions eluting from the column were collected into glass tubes containing
1/10 volume of 1 M Tris (pH 9.0) to neutralize the sample and then concentrated
and buffer exchanged into PBS using Vivaspin 6 (10-kDa cutoff; Sartorius)
concentrators. The protein concentration of each sample was determined by
using a Bradford assay (4) and adjusted with PBS to a concentration of 10 mg
ml1 for further use.
GIAs. Parasite invasion/GIAs were carried out with IgG purified from all sera,
in both Edinburgh and at the BPRC. BPRC “blinded” the samples before
dispatching them to Edinburgh on dry ice. Assays to test the ability of purified
IgG from the immunized rabbits to inhibit invasion and growth of P. falciparum
in cultures were carried out using Wellcome clone parasites in Edinburgh and
using FCR3, 3D7, and HB3 clone parasites at the BPRC. Three methods were
used to measure growth inhibition: (i) flow cytometric measurement of the
parasitemia and the increase in nucleic acid content of the parasite-infected red
blood cell, (ii) the parasite lactase dehydrogenase (pLDH) enzyme activity assay,
and (iii) microscopic observation of the growth and morphology of the parasite
in red blood cells.
Wellcome clone parasites were synchronized by three rounds of treatment
with 5% sorbitol. After purification, each of the 28 rabbit IgG antibody samples
(10 mg ml1) was serially diluted across six concentrations (neat, 1:1,1:2,1:4,1:8,
and 1:16) using IgG from unimmunized normal rabbit serum at the appropriate
concentrations to ensure that the same total concentration of IgG was present in
each sample. Then, 50 l of each IgG antibody dilution in PBS was dispensed in
triplicate into the wells of a Costar microtiter plate (Corning, New York, NY). A
portion (50 l) of parasite culture at 0.3% parasitemia and 2% hematocrit,
consisting mainly of mid-stage trophozoites, in twofold-concentrated normal
culture medium, was placed in each well. At the initiation of the assay period
therefore, parasites were present at 0.3% parasitemia in complete culture me-
dium at 1% hematocrit. Test cultures had rabbit IgG present at a starting
concentration of 5 mg ml1, serially double diluted to 0.15 mg ml1. Controls
contained (i) 5 mg of normal rabbit IgG ml1, (ii) no rabbit IgG (PBS), (iii)
culture in normal medium (10% human serum), or (iv) culture in normal me-
dium with uninfected red blood cells. Plates were gassed with 1% oxygen, 3%
carbon dioxide, and 96% nitrogen and then incubated at 37°C for 42 h.
After the 42-h incubation with the purified antibody, 50 l of well-mixed
parasites (Wellcome clone) from each assay well was dispensed into 0.25 ml of
cold PBS in a fresh microtiter plate (Immulon-4 HBX). The plates were loaded
into a Mistral 3000 centrifuge and centrifuged at 900  g for 10 min at 4°C. A
portion (0.24 ml) of supernatant was removed from each well, and the plates
frozen at 80°C for 30 min to lyse the pelleted cells. After the plates were
brought back to room temperature, 0.1 ml of complete pLDH substrate (100 mM
Tris-HCl [pH 7.5], 40 mM sodium L-lactate, and 0.25% Triton X-100 containing
0.2 g of nitroblue tetrazolium ml1, 1 l of 3-acetylpyridine adenine dinucleotide
ml1, and 0.2 U of Diaphorase ml1) was added to each well. Plates were kept
in the dark and read at 15, 30, and 60 min. The absorbance of wells in each plate
was measured at 650 nm on a Multiskan Ascent plate reader (Thermo Lab-
Systems), and the percent inhibition was calculated as 100  (A650 of the test
sample  A650 of the RBC only)/(A650 of normal rabbit serum control  A650 of
RBC only)  100 (12).
The BPRC used a slightly different protocol, where the effect of purified IgG
antibodies on parasite invasion was evaluated in triplicate using 96-well flat-
bottom plates (Greiner) with mature P. falciparum schizonts at a starting para-
sitemia of 0.2 to 0.4%, a hematocrit of 2%, and a final volume of 100 l
containing 10% normal human serum and 20 g of gentamicin ml1 in RPMI
1640. After 40 to 42 h, the cultures were mixed, and 50 l was transferred to 200
l of ice-cold PBS. The cultures were centrifuged, the supernatant was removed,
and the plates were then frozen. The parasitemia was estimated by using a pLDH
assay as described previously (12). Parasite growth inhibition, reported as a
percentage, was calculated as [100  (Aexperimental  Abackground)/(Acontrol 
Abackground)]  100, where A represent the absorbance value. Control IgG was
isolated from rabbits that had been immunized with adjuvant alone.
Flow cytometry. Portions (15 l) of well-mixed parasites (Wellcome isolate)
from the assay wells were placed into 0.25 ml of 0.01 mM thiazole orange in
FACSFlow buffer, followed by incubation for 15 min in the dark. The data from
these samples were then acquired on a Becton Dickinson FACScan fluorescence-
activated cell analyzer. The parasitemia in each sample was determined by using
CellQuest software. Fluorescent staining of parasites was detected in both the
FL2 and the FL3 channels, and the percent parasitemia was estimated for total
parasites and mature trophozoite and ring-form parasites. Data from 50,000 cells
were acquired for each sample.
Light microscopic assessment of stained parasites. In Edinburgh, after the
triplicate samples had been removed for the flow cytometry and pLDH assays,
the remaining sample material was pooled and concentrated by centrifugation.
Supernatant was removed, and thin smears were made from the concentrated red
blood cells. Slides were air dried, fixed with methanol, and then stained with 10%
Giemsa reagent for 45 min before washing and viewing the samples using oil
immersion light microscopy.
RESULTS
IFAs. The titers and staining patterns of the polyclonal an-
tisera from the rabbits immunized with the recombinant pro-
teins were compared by IFA. The results for each individual
rabbit antiserum are shown in Table 1. In the majority of cases,
the titers against the Wellcome clone and the 3D7 clone were
the same. If antibody titer to the 3D7 clone was different to
that observed against the Wellcome clone, that titer is given in
parentheses alongside. The arithmetic mean titer to the Well-
come parasites has been calculated for each group of rabbits
receiving the same antigen. All 28 postimmunization sera gave
a reaction above the corresponding preimmunization sera,
which were all negative at a 1:50 dilution (the highest concen-
tration tested).
Two different patterns were observed in the sera that gave
positive reactions. The first was that typical of a anti-MSP-1
antibody reaction in which the antisera reacted with all of the
stages of the parasite within the infected erythrocyte. The
second pattern was a punctate pattern observed on larger,
late-stage mature schizonts only and typical of anti-AMA-1
reactivity. However, not all large schizonts in these samples
showed the punctate fluorescence, possibly because the appar-
ent size of schizonts is only an approximate measure of matu-
rity. Since the frequency of positive reactions on an IFA slide
can influence the microscopic assessment of the IFA titer, all
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sera were retested on a second batch of slides from the Well-
come parasite clone, in which the overwhelming majority of
parasites were mature schizonts. The IFA endpoint titer for
each serum sample was recorded as the highest dilution at
which clear, parasite-specific fluorescent reactivity was seen.
Figure 1 shows a simple graphical representation of all of the
endpoint titers of the IFA assays for each rabbit.
The results indicate that the baculovirus-produced MSP-119
immunizations produced fourfold-higher parasite-specific an-
tibody titers than either of the two other single MSP-119 im-
munogens. This result was statistically significant in both cases
(Kruskal-Wallis test, P  0.05 in each case). The parasite-
specific antibodies were of comparable levels in the AMA-1
and the two AMA-1/MSP-119 coimmunization groups, with a
slight reduction in titer in the AMA-1/MSP-119 genetic hybrid
(which gave 1:1,600 titers in each rabbit tested). None of the
other between-group comparisons were statistically signifi-
cantly different (Kruskal-Wallis test, P  0.05 in all cases).
Rabbits 1 and 19 immunized with the AMA-1 antigen (alone
and combined, respectively) showed a substantially reduced
IFA titer against the 3D7A clone (heterologous to the AMA-1
antigen used) compared to the Wellcome clone (homologous
to the AMA-1 antigen). This suggests that the highly polymor-
phic AMA-1 antigen induces strain-specific antibodies, al-
though much larger sample sizes would be required for statis-
tical significance. In contrast, the three immunization groups
corresponding to the conserved MSP-119 alone showed the
same or similar assay results with both lines. Overall, as mea-
sured by IFA, the baculovirus MSP-119 product induced the
highest IFA titers, and the Pichia-derived MSP-119 products
gave the lowest titers of parasite-specific antibodies.
ELISAs. The individual antibody titers, arithmetic mean an-
tibody titers, and the standard deviations for each group of
rabbits with each immunogen tested are given in Table 2.
These data are shown graphically with the antibody titers for
each immunogen in Fig. 2. In general, ELISA titers for each
individual serum sample against the different MSP-119 antigens
were not significantly different (analysis of variance, Tukey-
Kraemer multiple-comparison test, P  0.6 in all cases). How-
ever, rabbits immunized with MSP-119 generally had slightly
higher titers to the homologous antigen than to MSP-119 re-
combinant protein derived from other expression systems. Bac-
ulovirus-produced MSP-119 showed this effect most strongly,
with 17 to 34% higher titers to the homologous baculovirus-
expressed MSP-119 than to either Pichia-expressed MSP-119
products (Table 2). Baculovirus MSP-119 induced between 5
and 12 times more antibodies than any other single MSP-1
immunogen and approximately three times more MSP-1 spe-
cific antibodies than the AMA-1–MSP-1 fusion. Titers to MSP-
119 were significantly higher in the baculovirus-immunized
group than in all other groups (Mann-Whitney U test, P 0.01
for all except MSP-119 WT, P  0.05). The ELISA results
shown here are those generated in Edinburgh; results gener-
ated at the BPRC using the same serum samples, but with
different positive control sera, were in very close accordance
(R2 for MSP-119-specific ELISA, 0.987; R
2 for AMA-1-specific
ELISA, 0.932 [Spearman rank correlation coefficient]).
Interestingly, some competitive effects were noted between an-
tigens when combined in a single immunization. Antibody titers
induced by immunization with the modified, Pichia-produced
MSP-119 alone were approximately twice that seen when the
same antigen was mixed with AMA-1, although this effect was not
statistically significant (Mann-Whitney U test, P 	 0.1508). In
contrast, no effect was seen on anti-AMA-1 titers after mixing
FIG. 1. Endpoint titers of groups of rabbit antisera as measured by
IFA. Individual IFA titers against P. falciparum-infected erythrocytes
for groups of sera from rabbits immunized with different recombinant
antigens are presented.
TABLE 1. Immunofluorescence titers of serum samples against
P. falciparum-infected red blood cells
Rabbit
serum
Titer
(3D7 titer)
Mean titer
(Wellcome) Pattern
a Immunogen
1 1:1,600 (1:400) 2,000 Punctate AMA-1
8 1:1,600 Punctate
15 1:3,200 Punctate
20 1:1,600 Punctate
2 1:1,600 960 All stages MSP-119 mut
10 1:400 (1:800) All stages
13 1:1,600 All stages
22 1:400 All stages
28 1:800 All stages
3 1:400 (1:800) 800 All stages MSP-119 WT
11 1:400 (1:800) All stages
14 1:800 All stages
21 1:1,600 All stages
4 1:1,600 2,240 All stages AMA-1 and
12 1:1,600 All stages MSP-119 mut
16 1:3,200 All stages
19 1:3,200 (1:400) All stages
26 1:1,600 All stages
5 1:1,600 1,600 All stages AMA-1-MSP-119
9 1:1,600 All stages mut fusion
18 1:1,600 All stages
24 1:1,600 All stages
25 1:1,600 All stages
6 1:1,600 3,520 All stages MSP-119
7 1:3,200 All stages baculovirus
17 1:3,200 All stages
23 1:3,200 All stages
27 1:6,400 All stages
Preimmune
control
1:50 No reactivity
Positive
control 1
(BPRC)
1:1,600 Punctate
Positive
control 2
(Pasteur)
1:1,600 All stages
a The punctate pattern was typical of reactivity with AMA-1 in mature schi-
zonts, whereas the reactivity with all parasite blood stages was typical of binding
to MSP-119.
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with the mutated MSP-119 recombinant protein. Conversely, a
significant increase in titer to MSP-119 was noted when the two
immunogens AMA-1 and MSP-119 were fused genetically
(Kruskal-Wallis test, P  0.01 for all MSP-119 antigens). ELISA
titers to the MSP-119 portion of the antigen were increased by 1.4-
to 1.7-fold compared to titers of antibodies induced in the rabbits
immunized with the modified MSP-119 alone and were 
3-fold
higher than the titers of rabbits immunized with the mixture of
AMA-1 and MSP-119. There was no adverse effect of the genetic
fusion on anti-AMA-1 titers compared to AMA-1 immunization
alone or to the mixture of AMA-1 and MSP-119. Rabbits immu-
nized with AMA-1 showed no significant difference in levels of
reactivity with both AMA-1and the AMA-1-MSP-119 fusion pro-
tein (Kruskal-Wallis test, P 	 0.9463).
Some rabbits (rabbits 2, 13, and 28, given the modified MSP-119
and rabbit 15 given AMA-1) showed detectable levels of, respec-
tively, AMA-1 or MSP-119 cross-reactive antibodies (10
4 to 105).
It is possible that this is due to low levels of P. pastoris contami-
nants in the immunogen or test antigen preparations. It might
also be due to rabbit serum antibodies cross-reacting with O-
linked glycosylate additions to the protein made by the yeast, a
phenomenon that has been noted with other recombinant pro-
teins produced with P. pastoris (D. R. Cavanagh et al., unpub-
lished data). No reagents were available to test for baculovirus
cross-contamination and cross-reactivity effects, although anti-
bodies induced with this antigen also showed the highest ELISA
titers against Pichia and E. coli MSP-119 homologues. It seems
unlikely that these antigens would have baculovirus or insect cell
contaminants.
Invasion and GIAs. (i) Flow cytometric and pLDH measure-
ment of growth inhibition. GIAs were carried out by adding
purified IgG to synchronized Wellcome (Edinburgh) or FCR3
FIG. 2. ELISA titers of sera from groups of rabbits immunized with different immunogens, as measured against different coating antigens.
Antibody titers for each group of rabbits are shown in separate panels, for each antigen on the ELISA plate. Sera from each immunization group
are arranged along the x axis. Circular symbols represent the median antibody titer in each group of rabbits, with bars representing the highest and
lowest titers in each group, expressed in ELISA units (see Materials and Methods).
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(BPRC) P. falciparum cultures. Control samples underwent an

10-fold increase (from 0.5 to 5% parasitemia) in the assays
shown. The percent growth inhibition was calculated as the
experimental growth relative to growth in the positive control
grown in the presence of unimmunized juvenile rabbit IgG. In
vitro culture growth, as measured by the flow cytometric de-
tection of thiazole orange-stained parasites, and the pLDH
enzymatic assay is shown as the median parasite growth inhi-
bition for the various immunization groups (Fig. 3). The data
obtained at both testing sites are compared in this figure, and
the results indicate that despite the minor differences the assay
conditions (described above), the pLDH assay gave similar
results in both laboratories. IgG induced by all experimental
vaccines showed a degree of inhibition at the antibody concen-
trations used (5 to 6 mg ml1). The median inhibition observed
was 85% for the three AMA-1-containing candidates, some-
what less for baculovirus MSP-119, and lowest for the two
Pichia MSP-119 antigens. It should be noted that the parasite
lines used for this comparison (Wellcome and FCR3) both
encode AMA-1 proteins homologous to the sequence of the
immunization construct used. Because of sequence polymor-
phism, the results obtained with this antigen can be highly
strain dependent. Due to the limited amounts of purified IgG
available, the pLDH results of Fig. 3 were the only GIA data
that were directly comparable between the Edinburgh and the
BPRC testing centers. A more complete pLDH based data set
was generated by the BPRC alone (see below).
Parasite growth inhibition measured by flow cytometry was
carried out only in Edinburgh and was always less than that
measured by the pLDH assay. This is due to the fact that flow
cytometry measures changes in the nucleic acid content of
parasite-infected erythrocytes. Parasite nuclei that have ceased
metabolic activity will be scored by this technique. This will
affect the extent of the increase in nucleic acid staining de-
tected between growth-impaired cultures and growth-unim-
paired cultures undergoing the rapid increase in nucleic acid
content that occurs during intra-erythrocytic parasite develop-
ment. The pLDH assay measures a parasite-specific enzyme
activity generated by active parasite metabolism with no con-
tribution to the measured signal from metabolically inert par-
asites.
(ii) pLDH measurement of growth inhibition at increasing
IgG concentrations with three different P. falciparum clones.
Figure 4 shows the results of pLDH assayed growth inhibition
at a range of concentrations of IgG (0.75 to 6 mg ml1) from
rabbits in each immunization group (shown as the average of
the four or five animals in each group). These titrated assays
were carried out at BPRC using cultures of the FCR3, HB3,
FIG. 3. Median percent parasite growth inhibition in the presence
of purified IgG from rabbits immunized with malaria vaccine candi-
dates. Each bar represents the median level of parasite growth inhibi-
tion for the IgG from each group of rabbits. For the Edinburgh data,
the 5-mg ml1 GIA results using the Wellcome parasite clone are
plotted compared to the BPRC data (at 6 mg ml1) using the FCR3
parasite clone. The number of parasites in each sample was measured
by using the pLDH levels and by flow cytometry after thiazole orange
staining of parasites (for the Wellcome clone only). Error bars indicate
the minimum and maximum inhibition levels within each group.
FIG. 4. Parasite GIA. The percent growth inhibition in cultures was measured by pLDH using three different clonal isolates of P. falciparum
(FCR3, HB3, and 3D7). Each panel represents the growth inhibition data obtained from each isolate. The average parasite growth inhibition for
each group of rabbits is plotted on the y axis against the IgG concentration (in mg ml1) on the x axis.
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and 3D7 cloned isolates of P. falciparum. Growth inhibition as
a percentage function of parasitemia compared to the control
is shown plotted against the IgG concentration. A marked
titration of the antibodies induced by immunization is observed
with each immunogen.
Growth inhibition against the FCR3 isolate (homologous for
the AMA-1 immunogen tested here) was strongest in animals
immunized with the AMA-1/MSP-119 fusion antigen, followed
by the two other AMA-1-containing immunization groups, at
the highest IgG concentration, although at lower concentra-
tions anti-baculovirus MSP-119 IgG inhibited as well as or
better than the others. Anti-baculovirus MSP-119 IgG showed
the best growth inhibition at all IgG concentrations with the
HB3 and 3D7 isolates (both nonhomologous to the AMA-1
immunogen used here), followed by the unfused and fused
AMA-1–MSP-119 combinations. Overall, the least growth in-
hibition was generally observed with antibodies to the two
Pichia MSP-119 recombinant products, a result also found in
the experiments shown in Fig. 3.
(iii) Correlation between flow cytometric and pLDH-based
measurements of parasite culture growth inhibition. To assess
comparability of the two methods used for measuring in vitro
culture growth inhibition in the presence of antibodies, the
percent growth inhibition as measured by flow cytometry in
Edinburgh and the pLDH assay at the BPRC was plotted
against the growth inhibition measured (in the same culture)
using the pLDH assay in Edinburgh (Fig. 5). Comparison of
the medians of the GIAs (taken as a whole since individual
groups are too small) shows that the pLDH GIA assays in
Edinburgh and the BPRC did not give significantly different
results (Friedman test of nonparametric repeated measures, P 
0.05 [analysis of variance]). As noted above, the flow cytomet-
ric measurements give consistently lower growth inhibition
percentages (Fig. 5) and therefore give significantly different
results from either pLDH assay (Friedman test, P  0.001).
This result is in agreement with the observations of Bergmann-
Leitner et al. (2), who demonstrated differences in growth
inhibition levels when using different nuclear staining dyes and
pLDH assays, probably due to the different sensitivities with
which these methods detect parasitemia and metabolic activity
in cultured parasites.
(iv) Microscopic analysis of parasite growth in the antibody
inhibition assays. In GIAs carried out in Edinburgh, Giemsa-
stained blood smears were also prepared for microscopy. Mi-
croscopically determined estimates of culture parasitemia cor-
related well with the measurements recorded by automated
flow cytometric analysis. Microscopy, however, permitted an
analysis of parasite morphology in samples treated with anti-
body relative to the controls. Correlating morphological obser-
vation of intra-erythrocytic growth stage with precise estima-
tion of the status of parasite nuclear division and the stage of
the cell cycle in the parasite is difficult, and the cell cycle of P.
falciparum is not completely understood (1). Without good
biochemical markers for cell cycle stages, estimates of the
“health” of P. falciparum cultures are necessarily subjective,
although experienced parasite cultivators can recognize declin-
ing cultures with unsatisfactory growth rates. However, numer-
ous parasites with abnormal morphology were observed in
growth-impaired cultures during the GIAs in the presence of
antibody. Examples of these abnormal intra-erythrocytic par-
asites, sometimes referred to as “crisis forms” (5), are shown in
Fig. 6.
The antibodies produced by different immunizations showed
certain consistent, but difficult to quantify, differences in their
effects on the in vitro-cultured parasites. In cultures grown in
the presence of anti-AMA-1 IgG, invasion was inhibited to
various degrees, but development of the postinvasion intra-
erythrocytic forms appeared normal. In contrast, in parasites
grown in the presence of anti-MSP-119 IgG, intra-erythrocytic
development frequently appeared abnormal, containing mis-
shapen rings and young trophozoites that appeared condensed
FIG. 5. Correlation between different methods for assaying in vitro
parasite culture growth inhibition. The percent inhibition of all 28
rabbit IgG samples in the study measured as parasitemia by flow
cytometry (in Edinburgh, open symbols) and pLDH assay (at BPRC,
solid symbols) is plotted on the y axis against the inhibition measured
using the same pLDH assay (x axis, Edinburgh pLDH assay). Solid
lines indicate trend lines for each data set; dotted lines represent 95%
confidence intervals for each trend line.
FIG. 6. Light microscopic comparison of normal P. falciparum tro-
phozoites and schizonts from untreated cultures and a range of abnor-
mally developing forms observed in cultures treated with anti-MSP-119
antibodies. Plates A to D, misshapen and crumpled early ring forms;
plates E and F, condensed and pycnotic early trophozoites; plates I to
L, mature trophozoites that appear deformed, swollen, and less
densely stained due to the appearance of vacuoles.
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and pycnotic, while more mature trophozoites often appeared
deformed, swollen, and less densely stained due to the appear-
ance of vacuoles. The micrographs shown in Fig. 6 show sev-
eral examples of the abnormal parasite morphologies seen in
cultures grown in the presence of anti-MSP-119 IgG. Similar
observations of the differential effects of antibodies on parasite
growth have been obtained in another recently published
study, also comparing functional assays of parasite growth in-
hibition (2).
DISCUSSION
Standardized immunogenicity measurements and in vitro
efficacy assays have not featured prominently in malaria vac-
cine research, and a systematic comparison is presented here
for the first time. Established laboratory procedures, logistical
and funding difficulties, intellectual property concerns, and the
competitive nature of the research process all inhibit objective
comparative analyses of different vaccine candidates. However,
there have been increasing calls to introduce industry-style
“critical path decision-making” into malaria vaccine develop-
ment, particularly since most competing vaccine development
projects currently use sequences derived from the same small
group of antigens. These antigens are being combined with a
wide variety of delivery technologies and platforms, but few
formulations have been compared for immunogenicity and
antigenicity, let alone in any in vitro assay that arguably might
have some correlation with the in vivo efficacy of a vaccine.
We compared the immunogenicity of six recombinant pro-
teins that are being considered as immunogens in possible
malaria vaccines. As measured by the concentrations of
actively parasite binding antibody detected by IFA, rabbits
immunized with the baculovirus produced MSP-119 had the
highest parasite-specific IFA titer of the group, followed by:
AMA-1MSP-119  AMA-1  AMA-1-MSP-119 fusion 
MSP-119 WT and MSP-119 mut (equal). Immunogenicity was
also measured by ELISA, although the original immunogens
used were not available as test antigens in all cases. Instead,
three different versions of MSP-119 were tested, plus two an-
tigens containing AMA-1. Again, the baculovirus-produced
MSP-119 product was the most immunogenic antigen tested.
It was also possible to demonstrate a good correlation be-
tween flow cytometric analysis, microscopy, and the pLDH
measurements of antibody-mediated growth inhibition. Some
parasite growth inhibition was seen in the presence of antibod-
ies raised by all of these immunogens. The inhibitory capacity
of the antibodies was overall the highest in rabbits immunized
with the baculovirus MSP-119 protein, using only 20-g doses
of a 6-year-old lyophilized preparation, attesting to its potency
and stability. Importantly, the inhibition was strain indepen-
dent. In contrast, the inhibitory capacity of antibodies induced
by the two Pichia MSP-119 antigens was overall the lowest.
Growth inhibition by antibodies to AMA-1 containing candi-
dates was intermediate, except at high IgG concentrations us-
ing a homologous parasite test strain, where they gave the best
inhibition. AMA-1 combination or fusion with MSP-119 gen-
erally elicited better inhibitory antibodies than did AMA-1
alone, although all tended to be strain dependent.
Taking all of the data together, the differences in antibody
binding and functional activity that we have attempted to as-
sess result from either or both of two causes: (i) the particular
protein being expressed induces more biologically relevant in-
hibitory or otherwise protective antibodies and/or (ii) the par-
ticular expression and purification systems used produced con-
formations of the antigen that were more immunogenic and/or
more like the native parasite antigen and thus better able to
induce inhibitory or otherwise protective antibodies.
Our data cannot differentiate between these possibilities.
We have noted that different recombinant constructs based on
the C terminus of MSP-1 are not in fact completely identical
protein sequences. For example, the baculovirus MSP-119
product tested here has sequences from the N-terminal block
1 region of MSP-1, fused to a slightly larger portion of the
C-terminal MSP-1 sequence than appears in the Pichia-derived
MSP-119 products (3). The block 1 region of MSP-1 is known
to contain at least one human T-cell epitope which might
enhance the immunogenicity of this product in both animals
and humans (17, 20).
Genetic fusion to create a recombinant hybrid protein of
AMA-1 and MSP-119 enhanced the immunogenicity of MSP-119.
However, simply mixing these individual components reduced the
MSP-119-specific titers in ELISA and IFA. Neither fusion nor
mixing appeared to affect the anti-AMA-1 titers. Thus, the mix-
ture of the two individual vaccine candidate components may
have resulted in some kind of immunological interference that led
to some suppression of the anti-MSP-119 IgG response in these
animals. This may be due to antigenic competition, a phenome-
non known to immunology for over 100 years, and noted in recent
immunizations with multiple recombinant malaria antigen plas-
mids (22). In some cases, a dominant antigen can prevent or
reduce the antibody response to another antigen, if the two are
administered simultaneously and in the same formulation. The
degree of suppression of the immune response is determined by
the relative quantities of the antigens in competition with each
other (15). Encouragingly, as stated earlier, the fusion of the two
antigens in one genetic construct ablated this effect and restored
the anti-MSP-119 titers to the levels seen with single immuniza-
tions, or higher (Fig. 2).
GIAs have attracted the attention of the malaria vaccine
field because they have been proposed to offer some correla-
tion with the in vivo efficacy of a vaccine and could potentially
be used as a prioritization tool. The correlation remains un-
proven, although it could be tested if significant amounts of
human sera from an at least partially successful clinical trial
were available. The assays are very sensitive to the in vitro
culture growth conditions of the parasite, and suboptimal ini-
tial parasitemia and relatively low parasite replication rates in
culture will translate into relatively small differences in the
growth inhibition and uninformative assay results. The lack of
“robustness” of the P. falciparum erythrocyte invasion-based in
vitro culture system itself remains a concern in the interpreta-
tion of GIA results. However, the GIA data obtained at both
testing sites were in very good agreement, following training of
operators in the NIH assay, at that facility.
This indicates that results that are repeatable in different
laboratories can be obtained, although this will be dependent
on strict adherence to common protocols and the use of pref-
erably identical, but at the very least agreed and equivalent
reagents, antibodies, and parasite clones. Simpler assays of the
immunogenicity of candidate antigens and more robust mea-
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sures of the functional activity of antibodies elicited by immu-
nization will continue to be developed. However, given the
complexity of the malaria parasite’s biology and the host’s
immune responses, interpretation of the biological relevance
of in vitro assay of blood-stage malaria vaccine candidates
requires a better understanding of the molecular mode of
action of the various specificities of anti-parasite antibodies
induced by both natural malaria infections and experimental
malaria vaccines.
There is a possibility that different antibodies, by binding
with different avidity and affinity to different parasite antigens,
might disrupt parasite development in different ways, a con-
clusion that has been reached independently in another recent
study (2). Anti-AMA-1 antibodies appeared to affect invasion
only, whereas there were indications that anti-MSP-1 antibod-
ies continued to affect postinvasion erythrocytic development
and led to a degree of inhibition of normal parasite develop-
ment. Clearly, these data are currently insufficient to draw any
strong conclusions about this phenomenon, but this observed
intra-erythrocytic inhibition of parasite growth is potentially
important and deserves further investigation. A two-cycle GIA
could increase the sensitivity of detection of growth-inhibitory
antibodies (18). Previous reports on evasion of antibody-me-
diated growth inhibition by allelic variants of AMA-1 indicate
that fundamental features of the assay, such as the choice of P.
falciparum culture isolate, can affect comparative assay out-
comes (2). Strain dependence is clearly an important parame-
ter in these types of functional assays and requires further
investigation because many P. falciparum antigens are very
polymorphic in nature and a successful malaria vaccine must
induce strain transcendent immunity.
These results clearly indicate that comparative preclinical
immunogenicity testing of different P. falciparum blood-stage
vaccine candidates can give discriminating results with regard
to several different parameters. Indeed, the baculovirus MSP-119
candidate proved to be superior by most of the criteria used.
Although the relevance of these criteria may be open to question
for a variety of reasons, there do not appear to be many obvious
alternatives at the present time for potential surrogate markers of
protective immunity in humans. In reality, no candidate has yet
been prioritized for clinical trials based on superior comparative
immunogenicity and/or growth inhibitory activity, although the
charitable foundations and funding bodies supporting malaria
vaccine research are considering moving in this direction (16).
Comparative immunogenicity testing will thus probably have a
growing role in the vaccine optimization process and in dissecting
immune responses following clinical trials. However, two major
factors still confound in vitro assay-based prioritization. The first
is the preparation and purity of the immunogens. Impure antigens
can be significantly more immunogenic than highly purified, ex-
pensively produced GMP-grade products. The second is the more
fundamental problem of the continuing lack of a proven correla-
tion between any of our in vitro assays and in vivo protection from
malaria.
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